

Li Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8289243/publications.pdf>

Version: 2024-02-01

15
papers

326
citations

933264

10
h-index

996849

15
g-index

15
all docs

15
docs citations

15
times ranked

485
citing authors

#	ARTICLE	IF	CITATIONS
1	Machine learning and bioinformatics analysis revealed classification and potential treatment strategy in stage 3–4 NSCLC patients. BMC Medical Genomics, 2022, 15, 33.	0.7	3
2	ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors. BMC Medicine, 2022, 20, 170.	2.3	15
3	Identification of CXCL13/CXCR5 axis–s crucial and complex effect in human lung adenocarcinoma. International Immunopharmacology, 2021, 94, 107416.	1.7	7
4	MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING. Cancer Discovery, 2021, 11, 2726-2737.	7.7	35
5	Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma. Scientific Reports, 2021, 11, 12727.	1.6	12
6	IQGAP3 interacts with Rad17 to recruit the Mre11-Rad50-Nbs1 complex and contributes to radioresistance in lung cancer. Cancer Letters, 2020, 493, 254-265.	3.2	18
7	Chemotherapeutic Tumor Microparticles Elicit a Neutrophil Response Targeting Malignant Pleural Effusions. Cancer Immunology Research, 2020, 8, 1193-1205.	1.6	40
8	CDK5 Activates Hippo Signaling to Confer Resistance to Radiation Therapy Via Upregulating TAZ in Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 758-769.	0.4	19
9	Human inflammatory dendritic cells in malignant pleural effusions induce Th1 cell differentiation. Cancer Immunology, Immunotherapy, 2020, 69, 779-788.	2.0	11
10	Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC. Clinical Cancer Research, 2020, 26, 3649-3661.	3.2	77
11	FOXA1+ regulatory T cells: A novel T cell subset that suppresses antitumor immunity in lung cancer. Biochemical and Biophysical Research Communications, 2019, 514, 308-315.	1.0	12
12	A hybrid of B and T lymphoblastic cell line could potentially substitute dendritic cells to efficiently expand out Her-2/neu-specific cytotoxic T lymphocytes from advanced breast cancer patients in vitro. Journal of Hematology and Oncology, 2017, 10, 63.	6.9	5
13	The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis. PLoS ONE, 2017, 12, e0173693.	1.1	30
14	Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy. Journal of Hematology and Oncology, 2016, 9, 66.	6.9	29
15	Anti-CD40-induced inflammatory E-cadherin+ dendritic cells enhance T cell responses and antitumor immunity in murine Lewis lung carcinoma. Journal of Experimental and Clinical Cancer Research, 2015, 34, 11.	3.5	13